oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes Patients with Oral Semaglutide and Cardiovascular Outcomes

SKU: 34539145128

Pay in 4 interest-free payments of $7.18 Learn more

Live Spec

Oral Semaglutide and Cardiovascular Outcomes in High Risk Type 2 Diabetes NEJM Sean C. Lucan, MD, MPH, MS semaglutide cardiovascular trial semaglutide and cardiovascular outcomes in patients with type 2 diabetes A new trial has reported that SOUL: Oral Semaglutide Bests Usual Care in High Risk Type 2 Diabetes Oral semaglutide is the first oral GLP 1 RA proven to reduce MACE in high risk T2DM patients, extending cardiovascular protection beyond injectable formulations. SOUL Trial: Oral Semaglutide & Cardiovascular Outcomes in T2DM SELECT Trial

Store: selfdriverentaluganda.com · Domain: selfdriverentaluganda.com